Clinical Trial Update: A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors [Phase 1, Phase 2]

View source ↗

Summary

An update on the Phase 1/2 study of CYT-0851 in B-cell malignancies and advanced solid tumors, noting completion of Phase 1/2 cohorts.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Diffuse Large B-cell Lymphoma
• Follicular Lymphoma
• Mantle Cell Lymphoma
• Multiple Myeloma
• Non-hodgkin Lymphoma
• Pancreatic Cancer
• Triple-negative Breast Cancer

Drugs mentioned

• CYT-0851

Snippet

Sponsor: Cyteir Therapeutics, Inc. | Conditions: Malignancy, Non-hodgkin Lymphoma | Phase 1, Phase 2 | Status: COMPLETED